Ashwagandha Drug Interactions: What You Need to Know Before Combining with Medications

Key Takeaways

Ashwagandha can raise thyroid hormone levels (T3 and T4), lower blood sugar, reduce cortisol, produce mild sedation through GABA pathways, and modulate immune activity. Each of these effects has the potential to add to or interfere with a medication that does the same thing. A 2026 comprehensive review of ashwagandha's endocrine effects confirmed that the herb modulates the HPA, HPG, and thyroid axes through indirect hormonal regulation rather than direct receptor binding (Vollmer & Brendler, 2026, Phytotherapy Research). The interactions below are organized by how strong the evidence is and how serious the consequences could be.

Understanding Ashwagandha Contraindications and Safety

Ashwagandha (Withania somnifera) is one of the most widely used adaptogenic herbs, with clinical trials spanning stress reduction, testosterone support, sleep quality, and body composition. Its strong safety profile in healthy adults often leads people to assume it is safe for everyone, including those on prescription medications. That assumption is mostly correct, but with important exceptions. The contraindications and drug interactions that exist are specific and manageable when you know what to look for. This article covers every major medication class with a documented or theoretical ashwagandha interaction, organized by clinical significance and evidence strength. Each section includes the mechanism, the evidence level, and practical guidance for what to do. For a general overview of ashwagandha side effects outside of drug interactions, start there.

How Ashwagandha Interacts with Medications

Ashwagandha does not block or accelerate the clearance of most drugs the way grapefruit or St. John's wort do. Its interactions are almost entirely additive, meaning it produces an effect that stacks on top of a medication doing the same thing. If a drug lowers blood sugar and ashwagandha also lowers blood sugar, the combination could push you too low. The mechanism matters because it means the risk is manageable with monitoring rather than requiring absolute avoidance in most cases.

Lab studies have shown that withanolides can inhibit certain CYP450 enzymes (particularly CYP2D6 and CYP3A4) in test-tube conditions. However, the concentrations used in those experiments are far higher than what reaches the liver after an oral dose of 600 mg of root extract. No published human pharmacokinetic study has demonstrated clinically meaningful CYP450 inhibition from ashwagandha at standard supplement doses. The interactions that matter in practice are pharmacodynamic (the herb and the drug do the same thing) rather than pharmacokinetic (the herb changes how the drug is processed).

One specific CYP450 concern worth addressing: CYP3A4 is the enzyme responsible for clearing many common drugs including atorvastatin, midazolam, and hormonal contraceptives. In vitro studies using high concentrations of withaferin A showed CYP3A4 inhibition, but oral ashwagandha root extract contains very little withaferin A (root-only extracts like KSM-66 are standardized away from it). A 2026 safety study measuring liver function markers monthly for 12 months in 191 adults taking 600 mg/day of KSM-66 found no changes in hepatic enzyme activity consistent with CYP450 disruption (Salve et al., 2025). This further supports the conclusion that CYP450-mediated interactions are a lab finding that does not translate to clinical practice at standard doses.

This distinction is important because it means the long lists of "479 interactions" you see on drug-checker databases are mostly theoretical CYP450 flags generated by software. The clinically relevant interactions are a much shorter list, covered below. For ashwagandha's general safety profile, see ashwagandha side effects.

Ashwagandha and Thyroid Medications

This is the best-documented and most clinically significant interaction. Ashwagandha can raise serum T3 and T4 levels, which may add to the effects of thyroid replacement drugs like levothyroxine (Synthroid, Levoxyl) and liothyronine (Cytomel).

The evidence comes from a double-blind, placebo-controlled RCT in 50 patients with subclinical hypothyroidism. Eight weeks of ashwagandha root extract (600 mg/day) normalized TSH and significantly raised serum T3 and T4 compared to placebo (Sharma et al., 2018, J Altern Complement Med). A 2026 narrative review confirmed that ashwagandha elevates thyroid hormones specifically in hypothyroid contexts, with no evidence of the same effect in euthyroid (normal thyroid) individuals (Vollmer & Brendler, 2026).

What this means in practice: if you take levothyroxine and add ashwagandha, your effective thyroid hormone level could rise beyond what your prescriber intended. Symptoms of excess thyroid hormone include rapid heart rate, tremor, anxiety, heat intolerance, and unintended weight loss. If you are on thyroid medication and want to try ashwagandha, have your TSH and free T4 checked 6 to 8 weeks after starting. Your prescriber may need to adjust your levothyroxine dose downward. Do not start both simultaneously or change doses without medical guidance.

A separate concern applies to people with autoimmune thyroid conditions. Hashimoto's thyroiditis involves immune-mediated destruction of the thyroid gland, and ashwagandha's immunostimulatory properties could theoretically accelerate that process. No published study has tested ashwagandha specifically in Hashimoto's patients, and the Sharma 2018 trial excluded autoimmune thyroid disease. Similarly, people with Graves' disease (autoimmune hyperthyroidism) should avoid ashwagandha because raising already-elevated thyroid hormones could worsen symptoms. The bottom line: any thyroid condition, whether hypo or hyper, medicated or unmedicated, warrants a conversation with your endocrinologist before using ashwagandha.

Ashwagandha and Diabetes Medications

Ashwagandha may lower blood glucose, which could add to the effect of metformin, sulfonylureas, or insulin and increase the risk of hypoglycemia.

The glucose-lowering effect has been observed in some clinical trials, though it is modest and inconsistent across studies. The most likely mechanism is cortisol reduction: chronically elevated cortisol raises blood sugar through gluconeogenesis, and lowering cortisol removes that upward pressure on glucose. A 2025 systematic review and meta-analysis of ashwagandha's cortisol effects (15 RCTs, 873 participants) confirmed significant cortisol reductions of 2.36 µg/dL on average (Bachour et al., 2025, BJPsych Open), which could indirectly affect fasting glucose in people already on glucose-lowering medications.

The practical risk is relatively low for most people. Ashwagandha is not a potent hypoglycemic agent, and the blood sugar drop, if it occurs at all, tends to be small. But if you are on tight glycemic control with insulin or a sulfonylurea (drugs that can cause frank hypoglycemia), even a small additional drop matters. Monitor your blood glucose more frequently for the first few weeks after adding ashwagandha, and alert your prescriber to the addition.

An important nuance: the cortisol-mediated blood sugar reduction would be most pronounced in people who are chronically stressed, since that is where cortisol levels have the most room to fall. A 2019 dose-response RCT in stressed adults found that ashwagandha significantly reduced perceived stress scores and serum cortisol at both 250 mg/day and 600 mg/day compared to placebo (Salve et al., 2019, Cureus). People who are not stressed are unlikely to experience meaningful cortisol changes and therefore unlikely to see their blood sugar shift. This context helps calibrate the actual risk: a healthy, unstressed person on metformin for mild type 2 diabetes is at lower risk than a chronically stressed person on insulin with tight targets.

Ashwagandha and Antidepressants (SSRIs, SNRIs, Wellbutrin)

Ashwagandha has anxiolytic properties that work through GABA modulation and cortisol reduction. Combining it with prescription antidepressants creates a theoretical additive effect on mood and sedation, though no serious adverse interactions have been reported in published literature.

The most commonly searched combinations are ashwagandha with escitalopram (Lexapro), sertraline (Zoloft), bupropion (Wellbutrin), fluoxetine (Prozac), and duloxetine (Cymbalta). None of these have been studied in a controlled trial combining the drug with ashwagandha. The concern is theoretical and pharmacodynamic: both the drug and the herb reduce anxiety and modulate neurotransmitter activity, so the combination could produce excess sedation or emotional blunting in sensitive individuals.

Ashwagandha does not appear to be a serotonin reuptake inhibitor, which means the risk of serotonin syndrome (a dangerous interaction that occurs when multiple serotonergic agents are combined) is not supported by current evidence. A 2026 clinical pharmacist review of ashwagandha drug interactions classified the SSRI interaction risk as low, noting that most predicted serotonergic effects from ashwagandha have not materialized in clinical use. That said, if you notice unusual drowsiness, emotional flatness, or agitation after adding ashwagandha to an antidepressant regimen, reduce or discontinue the supplement and tell your prescriber. For the broader stress and cortisol reduction evidence, see our dedicated article.

Timing can help manage any additive sedation. If you take your SSRI in the morning and ashwagandha in the evening before bed, the peak sedative effects are separated by several hours. This approach uses ashwagandha's calming properties to support sleep while keeping the daytime effects of your antidepressant undiluted. For people who take their SSRI at night, adding ashwagandha at the same time may produce noticeable next-morning grogginess. Experiment with a 300 mg dose before changing to 600 mg, and keep a simple journal of sleep quality and daytime alertness for the first two weeks.

Ashwagandha and Sedatives or Sleep Medications

Ashwagandha has documented sedative effects through GABAergic modulation. Combining it with benzodiazepines (Xanax, Ativan, Klonopin), zolpidem (Ambien), or other CNS depressants could produce excessive drowsiness.

The sedative mechanism involves triethylene glycol and other active compounds in ashwagandha that promote sleep onset. A 2017 preclinical study identified triethylene glycol as the specific sleep-inducing component (Kaushik et al., 2017, PLoS One), and multiple clinical trials have confirmed improvements in sleep quality and onset latency in human participants. A 2026 case report documented parasomnia, acute confusion, and transient amnesia in a patient taking ashwagandha, likely mediated by GABAergic effects with individual variability in metabolism.

If you use a prescribed sedative or sleep aid, adding ashwagandha could amplify the drowsiness beyond what you expect. This is especially relevant for older adults, people who operate heavy machinery, and anyone already sensitive to sedating substances. Start with a low dose (300 mg) and take it at a time when increased drowsiness would be safe (before bed, and away from driving or operating machinery). For ashwagandha's sleep effects in detail, see ashwagandha for sleep.

The 2025 case report of parasomnia and transient amnesia is instructive: a 40-year-old man without prior psychiatric history developed prolonged sleep, abnormal sleep behaviors, acute confusion, and retrograde amnesia after starting ashwagandha. All symptoms resolved completely after discontinuation. The authors attributed the reaction to GABAergic modulation combined with individual variability in drug metabolism. This is an extreme outlier, but it illustrates why combining ashwagandha with a prescribed sedative requires caution. For people who already experience paradoxical reactions to GABAergic drugs (becoming agitated rather than calm on benzodiazepines, for instance), ashwagandha may carry a similar unpredictability. For details on how long ashwagandha takes to work and onset timing, see our guide.

Ashwagandha and Blood Pressure Medications

Ashwagandha may produce a mild reduction in blood pressure through cortisol lowering. If you take antihypertensives (lisinopril, amlodipine, losartan, metoprolol), the combination could cause blood pressure to drop too low.

The blood pressure effect is secondary to cortisol reduction and stress modulation rather than direct vasodilation. It is modest in magnitude. No published case report has documented clinically dangerous hypotension from ashwagandha combined with a blood pressure medication. However, the theoretical additive risk is real enough that consensus clinical references (including the NIH Office of Dietary Supplements and Natural Medicines Comprehensive Database) flag it.

Practical advice: if you are on blood pressure medication and start ashwagandha, monitor your blood pressure at home for the first two to four weeks. Watch for symptoms of low blood pressure like dizziness when standing, lightheadedness, or unusual fatigue. If your readings consistently drop below your target range, your prescriber may need to reduce the antihypertensive dose.

A common question: does ashwagandha affect heart rate? Cortisol elevation increases heart rate through sympathetic nervous system activation, and lowering cortisol can reduce resting heart rate modestly. This is generally a positive effect in a stressed person, but it could compound the heart-rate-lowering effect of beta-blockers like metoprolol or atenolol. If you are on a beta-blocker and notice your resting heart rate dropping below 55 bpm after starting ashwagandha, flag it at your next cardiology appointment. For most people on ACE inhibitors (lisinopril, enalapril) or ARBs (losartan, valsartan), the additive blood pressure effect is too small to be clinically concerning at ashwagandha doses of 300 to 600 mg/day.

Ashwagandha and Immunosuppressants

Ashwagandha has documented immunostimulatory properties. If you take immunosuppressive drugs after an organ transplant (tacrolimus, cyclosporine, mycophenolate) or for an autoimmune condition (methotrexate, azathioprine), ashwagandha could work against the drug and increase rejection or flare risk.

This interaction is based on mechanism rather than case reports: ashwagandha upregulates NK cell activity, increases immunoglobulin production, and modulates T-cell responses. These are beneficial effects in a healthy person but potentially dangerous in someone whose immune system is being intentionally suppressed. The Vollmer and Brendler 2026 review noted that ashwagandha's immune-modulating properties are well-documented and clinically relevant for patients on immunosuppressive therapy.

The recommendation here is straightforward: if you take any immunosuppressant medication, do not use ashwagandha without explicit clearance from the prescribing physician. This is one of the few categories where the interaction risk justifies avoidance rather than just monitoring.

The same caution extends to autoimmune conditions that may not require immunosuppressive drugs. Rheumatoid arthritis, lupus, multiple sclerosis, and inflammatory bowel disease all involve an overactive immune system, and ashwagandha's immune-stimulating properties could theoretically worsen the underlying disease activity. Some Ayurvedic practitioners use ashwagandha for autoimmune conditions based on its anti-inflammatory and adaptogenic effects, but the immunostimulatory component introduces a real risk that has not been adequately studied in controlled trials. Until clinical data specific to autoimmune populations exists, treating ashwagandha as contraindicated in active autoimmune disease is the safer approach. For people with autoimmune conditions in stable remission (no active flares, stable labs), the decision is more nuanced and should involve the treating rheumatologist or gastroenterologist.

Ashwagandha and Birth Control

There is no published evidence that ashwagandha reduces the effectiveness of hormonal birth control (combined pill, progestin-only pill, patch, ring, or IUD).

Ashwagandha does modulate hormones, but its effects run through the HPA and HPG axes rather than through direct estrogen or progesterone receptor binding. The Vollmer and Brendler 2026 review explicitly noted that ashwagandha's hormonal effects are indirect and do not appear to act through nuclear steroid hormone receptors. This means it is mechanistically different from enzyme inducers like St. John's wort or rifampin, which accelerate the hepatic clearance of contraceptive hormones and genuinely reduce their effectiveness.

That said, no controlled study has specifically tested ashwagandha's effect on contraceptive hormone levels. The absence of evidence is not evidence of absence. If contraceptive reliability is critical for you, mention ashwagandha use to your gynecologist at your next visit. Based on current data, no dose adjustment or backup method appears necessary, but the question has not been formally studied.

To put this in practical context: St. John's wort, the herbal supplement with the best-documented contraceptive interaction, works by inducing CYP3A4, which accelerates the clearance of ethinylestradiol and progestins. This mechanism has been confirmed in pharmacokinetic studies. Ashwagandha does not induce CYP3A4 at supplement doses. Its hormonal effects are indirect, working through the HPA axis rather than through enzyme induction. The two supplements are mechanistically different in the way that matters for contraceptive safety. This is relevant because "herbal supplement interacts with birth control" is a common concern that often conflates all herbs into one category.

Ashwagandha and Stimulants (Adderall, Vyvanse)

Ashwagandha's calming, GABAergic effects could theoretically oppose the stimulating effects of amphetamine-based ADHD medications. The result could be reduced perceived effectiveness of the stimulant, though no published case report or trial has documented this.

Some users report that ashwagandha "takes the edge off" stimulant-related anxiety and jitteriness, which they experience as a benefit rather than a problem. Others find that it dampens the focus-enhancing effect they are taking the stimulant for. The interaction is pharmacodynamic (opposing effects on arousal) rather than pharmacokinetic, and the outcome depends on individual neurobiology. If you try this combination, do it on a day when reduced stimulant effectiveness would be inconsequential, and track your response before making it routine.

Ashwagandha and Liver Health

Rare but real cases of ashwagandha-associated liver injury have been reported. If you take any medication known to stress the liver (statins, acetaminophen at high doses, certain antifungals), adding ashwagandha introduces a theoretical additive hepatotoxic risk.

A 2026 scoping review synthesized 13 publications covering 25 patients with ashwagandha-associated liver injury worldwide. The pattern was predominantly cholestatic (bile-flow obstruction, 44% of cases) rather than hepatocellular cell death (32%), and most patients recovered after discontinuation over weeks to months (McIntyre et al., 2026, Cureus). Severe outcomes were rare and concentrated in patients with pre-existing cirrhosis. An earlier case series from India documented 8 confirmed single-ingredient cases out of 23 total liver injury presentations (Philips et al., 2023, Hepatol Commun). The NIH LiverTox database classifies the risk as rare and idiosyncratic, meaning it appears to be an unpredictable individual susceptibility rather than a dose-dependent toxicity.

Practical guidance: if you develop jaundice (yellow skin or eyes), dark urine, persistent nausea, or right-upper-quadrant abdominal pain while taking ashwagandha, stop immediately and see a physician. These symptoms are rare but require prompt evaluation. The 12-month safety study of KSM-66 at 600 mg/day showed no hepatic abnormalities in any participant (Salve et al., 2025, Phytotherapy Research), which provides reassurance for the general population but does not eliminate individual risk.

Product quality likely plays a role in hepatotoxicity reports. The McIntyre 2026 scoping review noted that many published cases involved products with unclear sourcing, mixed-ingredient formulations, or no independent quality verification. Leaf-containing extracts have higher concentrations of withaferin A, a compound with documented cytotoxic properties, compared to root-only extracts. This is one reason the choice of extract type matters: a root-only extract like KSM-66 (standardized to 5 percent withanolides with minimal withaferin A) has a different safety profile than a leaf-containing extract or an uncharacterized powder. For more on extract selection, see KSM-66 vs regular ashwagandha extract. For dosage guidance matched to clinical trial protocols, see our dosage article.

Who Should Not Take Ashwagandha

Some groups should avoid ashwagandha entirely based on current evidence and safety principles. Others can use it with medical supervision and appropriate monitoring.

Avoid entirely

Pregnant or breastfeeding women (animal studies show potential abortifacient effects at high doses, and no human safety data exists for pregnancy). Women who are trying to conceive should discuss ashwagandha with their OB-GYN; while some evidence suggests benefits for reproductive hormone balance, the safety profile during early pregnancy is unknown, and stopping an established supplement upon discovering pregnancy introduces its own variables.

People taking immunosuppressant drugs after organ transplant. Anyone with active liver disease or unexplained elevated liver enzymes. People scheduled for surgery within two weeks (ashwagandha's mild effects on blood pressure, blood sugar, and thyroid hormones could complicate anesthesia management; most surgeons recommend stopping all supplements 7 to 14 days before elective procedures).

Use only with prescriber supervision

People on thyroid medication (levothyroxine, liothyronine). People on diabetes medication, particularly insulin or sulfonylureas. People on blood pressure medication who already run low. People on sedatives or CNS depressants. People with autoimmune conditions, whether medicated or not, since immune stimulation could trigger flares.

Generally safe to combine (monitor as needed)

SSRIs and SNRIs at stable doses (watch for excess sedation). Stimulant ADHD medications (watch for reduced perceived effect). Hormonal birth control (no evidence of interaction, but mention to your prescriber). Statins (hepatotoxic risk is theoretical and very low at standard ashwagandha doses). For a broader look at ashwagandha benefits and how they relate to your health goals, start there. To compare standardized extracts, see what is KSM-66 and best KSM-66 ashwagandha supplements.

Ashwagandha During Pregnancy and Breastfeeding

Ashwagandha is classified as "likely unsafe" during pregnancy by the Natural Medicines Comprehensive Database. No human pregnancy safety study exists.

The concern is based on animal studies showing uterine stimulant and potential abortifacient activity of withanolides at high doses. Whether these effects occur at standard human supplement doses (300 to 600 mg/day of root extract) is unknown, because no researcher has or likely will conduct a pregnancy trial with a herbal supplement that has abortifacient signals in animals. The precautionary principle applies: avoid during pregnancy.

For breastfeeding, the data gap is similar. No study has measured whether withanolides pass into breast milk or what effects they might have on a nursing infant. Traditional Ayurvedic sources sometimes recommend ashwagandha for postpartum recovery, but traditional use does not substitute for controlled safety data. Until human lactation studies are published, the recommendation is to avoid ashwagandha while breastfeeding. For women looking for stress support during the postpartum period, discuss evidence-based alternatives with your OB-GYN or midwife. For ashwagandha use in women generally, including the menstrual cycle and perimenopause evidence, see our dedicated page.

Ashwagandha Drug Interactions List

The table below summarizes the major categories of medication interactions, the mechanism, the evidence level, and the recommended action.

How to Talk to Your Prescriber About Ashwagandha

Many physicians and pharmacists are unfamiliar with ashwagandha. Walking in and saying "I want to take this herb" often gets a reflexive "don't take anything herbal with your medication" response that is unhelpful. A more productive approach is to bring specific information.

What to say: "I am considering ashwagandha root extract (KSM-66, 600 mg/day). It has documented effects on thyroid hormones [Sharma 2018, J Altern Complement Med] and cortisol [Bachour 2025 meta-analysis]. I want to know if it could interact with [your specific medication]." This gives your prescriber something concrete to evaluate (for our full roundup of stress supplements, see best supplements for stress). This also gives rather than asking them to assess an unknown herb from memory.

What to bring: this article, or a printout of the interaction summary table above. The Sharma 2018 thyroid RCT and the Salve 2025 12-month safety study are the two most useful references for a clinical conversation, because they provide the type of controlled data prescribers are trained to interpret.

What to ask for: baseline labs before starting (TSH, fasting glucose, liver panel) and a recheck at 6 to 8 weeks. This gives both you and your prescriber objective data to evaluate whether ashwagandha is affecting the medications you take. If the labs are unchanged, you have evidence of safety in your specific case. If something shifts, you catch it early and can adjust. For the recommended timing of ashwagandha relative to your medications, see our guide.

Frequently Asked Questions

References